Stock Analiz

Maravai Lifesciences Holdings, Inc. (MRVI) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Maravai Lifesciences’s revenue went from $143M in fiscal 2019 to $186M in fiscal 2025, growth of about 4.4% a year.

Net income in fiscal 2025 was -$131M, a net margin of -70.4%; the best year in this period was 2022 with $220M.

Over the twelve months to September 30, 2026, revenue was $213M and net income -$66M.

Free cash flow was -$71M in fiscal 2025 and positive in 5 of the 7 years shown.

The diluted share count fell 43% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2019: $143M20192020: $284M20202021: $799M20212022: $883M20222023: $289M20232024: $259M20242025: $186M2025$186M
Net income
2019: -$4M20192020: $89M20202021: $182M20212022: $220M20222023: -$119M20232024: -$145M20242025: -$131M2025-$131M
Free cash flow
2019: $7M20192020: $127M20202021: $354M20212022: $519M20222023: $61M20232024: -$22M20242025: -$71M2025-$71M
EPS (diluted)
2019: $-0.0320192020: $2.3620202021: $1.5620212022: $1.6720222023: $-0.9020232024: $-1.0520242025: $-0.902025$-0.90

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$213M$186M$259M$289M$883M$799M$284M$143M
Gross profit$83M$34M$108M$140M$714M$659M$204M$76M
Operating income-$97M-$215M-$236M-$32M$574M$555M$120M$24M
Net income-$66M-$131M-$145M-$119M$220M$182M$89M-$4M
EPS (diluted)$-0.43$-0.90$-1.05$-0.90$1.67$1.56$2.36$-0.03
R&D$15M$17M$19M$17M$18M$15M$9M$4M
Revenue growth—−28.3%−10.3%−67.3%+10.5%+181.3%+98.5%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$5M-$58M$7M$126M$536M$369M$152M$24M
Capital spending-$8M-$13M-$30M-$66M-$17M-$15M-$25M-$17M
Free cash flow-$13M-$71M-$22M$61M$519M$354M$127M$7M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————$0$0$34M$0
Stock-based pay$31M$30M$49M$35M$19M$10M$25M$2M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$217M$322M$575M$632M$551M$236M$25M
Debt—$334M$345M$578M$585M$575M$535M—
Equity—$212M$325M$417M$545M$315M$89M$145M
Total assets—$771M$1.0B$1.5B$2.3B$1.9B$1.3B—
Shares (diluted)—144M138M132M255M258M29M254M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin39.1%18.3%41.8%48.5%80.9%82.4%72.0%53.3%
Operating margin-45.4%-115.9%-90.9%-10.9%65.0%69.4%42.2%16.8%
Net margin-30.8%-70.4%-55.9%-41.2%24.9%22.8%31.3%-3.1%
FCF margin-6.2%-38.1%-8.6%21.0%58.8%44.3%44.6%4.9%
ROIC—-38.7%-34.9%-2.5%45.2%55.0%18.6%14.7%
ROE—-61.6%-44.5%-28.6%40.4%57.7%100.5%-3.1%

Frequently asked questions

What is Maravai Lifesciences’s annual revenue?

$186M in fiscal 2025 and $213M over the twelve months to September 30, 2026.

How much profit does Maravai Lifesciences make?

Net income was -$131M in fiscal 2025 (net margin -70.4%).

Is Maravai Lifesciences’s revenue growing?

No: revenue fell 28.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.